世界の先天性インスリン過剰症市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Congenital Hyperinsulinism Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-4047
• 出版社/出版日：QYResearch / 2021年6月
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、96ページ
• 納品方法：Eメール（納期：3日）
• 産業分類：医療

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

QYResearch社発行の本調査レポートでは、先天性インスリン過剰症の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（手術、医薬品、その他）、用途別市場規模（病院、診療所、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。
・市場概要
・先天性インスリン過剰症の市場動向
・企業の競争状況、市場シェア
・先天性インスリン過剰症の種類別市場規模と予測2016-2027（手術、医薬品、その他）
・先天性インスリン過剰症の用途別市場規模と予測2016-2027（病院、診療所、その他）
・先天性インスリン過剰症の北米市場規模2016-2027（アメリカ、カナダ）
・先天性インスリン過剰症の欧州市場規模2016-2027（ドイツ、フランス、イギリス等）
・先天性インスリン過剰症のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等）
・先天性インスリン過剰症の中南米市場規模2016-2027（メキシコ、ブラジル）
・先天性インスリン過剰症の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等）
・主要企業情報（IVAX Pharmaceuticals、Teva Pharmaceuticals、Zealand Pharma、Rezolute、Xeris Pharmaceuticals、Eiger BioPharmaceuticals、AmideBio、Recordati）
・結論

Congenital hyperinsulinism (CHI) is a condition that causes individuals to have abnormally high levels of insulin, which is a hormone that helps control blood sugar levels. People with this condition have frequent occurrences of low blood sugar (hypoglycemia). In infants and young children, these occurrences are characterized by a lack of energy (lethargy), irritability, or difficulty feeding. Repeated episodes of low blood sugar increase the risk for serious complications such as breathing difficulties, seizures, intellectual disability, vision loss, brain damage, and coma.

Market Analysis and Insights: Global Congenital Hyperinsulinism Market
The global Congenital Hyperinsulinism market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Congenital Hyperinsulinism market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Congenital Hyperinsulinism market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Congenital Hyperinsulinism market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Congenital Hyperinsulinism market.

Global Congenital Hyperinsulinism Scope and Market Size
Congenital Hyperinsulinism market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Congenital Hyperinsulinism market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Surgery
Medication
Others

Segment by Application
Hospital
Clinic
Others

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
IVAX Pharmaceuticals
Teva Pharmaceuticals
Zealand Pharma
Rezolute
Xeris Pharmaceuticals
Eiger BioPharmaceuticals
AmideBio
Recordati

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Congenital Hyperinsulinism Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Surgery
1.2.3 Medication
1.2.4 Others
1.3 Market by Application
1.3.1 Global Congenital Hyperinsulinism Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Congenital Hyperinsulinism Market Perspective (2016-2027)
2.2 Congenital Hyperinsulinism Growth Trends by Regions
2.2.1 Congenital Hyperinsulinism Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Congenital Hyperinsulinism Historic Market Share by Regions (2016-2021)
2.2.3 Congenital Hyperinsulinism Forecasted Market Size by Regions (2022-2027)
2.3 Congenital Hyperinsulinism Industry Dynamic
2.3.1 Congenital Hyperinsulinism Market Trends
2.3.2 Congenital Hyperinsulinism Market Drivers
2.3.3 Congenital Hyperinsulinism Market Challenges
2.3.4 Congenital Hyperinsulinism Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Congenital Hyperinsulinism Players by Revenue
3.1.1 Global Top Congenital Hyperinsulinism Players by Revenue (2016-2021)
3.1.2 Global Congenital Hyperinsulinism Revenue Market Share by Players (2016-2021)
3.2 Global Congenital Hyperinsulinism Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Congenital Hyperinsulinism Revenue
3.4 Global Congenital Hyperinsulinism Market Concentration Ratio
3.4.1 Global Congenital Hyperinsulinism Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Congenital Hyperinsulinism Revenue in 2020
3.5 Congenital Hyperinsulinism Key Players Head office and Area Served
3.6 Key Players Congenital Hyperinsulinism Product Solution and Service
3.7 Date of Enter into Congenital Hyperinsulinism Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Congenital Hyperinsulinism Breakdown Data by Type
4.1 Global Congenital Hyperinsulinism Historic Market Size by Type (2016-2021)
4.2 Global Congenital Hyperinsulinism Forecasted Market Size by Type (2022-2027)

5 Congenital Hyperinsulinism Breakdown Data by Application
5.1 Global Congenital Hyperinsulinism Historic Market Size by Application (2016-2021)
5.2 Global Congenital Hyperinsulinism Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Congenital Hyperinsulinism Market Size (2016-2027)
6.2 North America Congenital Hyperinsulinism Market Size by Type
6.2.1 North America Congenital Hyperinsulinism Market Size by Type (2016-2021)
6.2.2 North America Congenital Hyperinsulinism Market Size by Type (2022-2027)
6.2.3 North America Congenital Hyperinsulinism Market Size by Type (2016-2027)
6.3 North America Congenital Hyperinsulinism Market Size by Application
6.3.1 North America Congenital Hyperinsulinism Market Size by Application (2016-2021)
6.3.2 North America Congenital Hyperinsulinism Market Size by Application (2022-2027)
6.3.3 North America Congenital Hyperinsulinism Market Size by Application (2016-2027)
6.4 North America Congenital Hyperinsulinism Market Size by Country
6.4.1 North America Congenital Hyperinsulinism Market Size by Country (2016-2021)
6.4.2 North America Congenital Hyperinsulinism Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Congenital Hyperinsulinism Market Size (2016-2027)
7.2 Europe Congenital Hyperinsulinism Market Size by Type
7.2.1 Europe Congenital Hyperinsulinism Market Size by Type (2016-2021)
7.2.2 Europe Congenital Hyperinsulinism Market Size by Type (2022-2027)
7.2.3 Europe Congenital Hyperinsulinism Market Size by Type (2016-2027)
7.3 Europe Congenital Hyperinsulinism Market Size by Application
7.3.1 Europe Congenital Hyperinsulinism Market Size by Application (2016-2021)
7.3.2 Europe Congenital Hyperinsulinism Market Size by Application (2022-2027)
7.3.3 Europe Congenital Hyperinsulinism Market Size by Application (2016-2027)
7.4 Europe Congenital Hyperinsulinism Market Size by Country
7.4.1 Europe Congenital Hyperinsulinism Market Size by Country (2016-2021)
7.4.2 Europe Congenital Hyperinsulinism Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Congenital Hyperinsulinism Market Size (2016-2027)
8.2 Asia-Pacific Congenital Hyperinsulinism Market Size by Type
8.2.1 Asia-Pacific Congenital Hyperinsulinism Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Congenital Hyperinsulinism Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Congenital Hyperinsulinism Market Size by Type (2016-2027)
8.3 Asia-Pacific Congenital Hyperinsulinism Market Size by Application
8.3.1 Asia-Pacific Congenital Hyperinsulinism Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Congenital Hyperinsulinism Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Congenital Hyperinsulinism Market Size by Application (2016-2027)
8.4 Asia-Pacific Congenital Hyperinsulinism Market Size by Region
8.4.1 Asia-Pacific Congenital Hyperinsulinism Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Congenital Hyperinsulinism Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Congenital Hyperinsulinism Market Size (2016-2027)
9.2 Latin America Congenital Hyperinsulinism Market Size by Type
9.2.1 Latin America Congenital Hyperinsulinism Market Size by Type (2016-2021)
9.2.2 Latin America Congenital Hyperinsulinism Market Size by Type (2022-2027)
9.2.3 Latin America Congenital Hyperinsulinism Market Size by Type (2016-2027)
9.3 Latin America Congenital Hyperinsulinism Market Size by Application
9.3.1 Latin America Congenital Hyperinsulinism Market Size by Application (2016-2021)
9.3.2 Latin America Congenital Hyperinsulinism Market Size by Application (2022-2027)
9.3.3 Latin America Congenital Hyperinsulinism Market Size by Application (2016-2027)
9.4 Latin America Congenital Hyperinsulinism Market Size by Country
9.4.1 Latin America Congenital Hyperinsulinism Market Size by Country (2016-2021)
9.4.2 Latin America Congenital Hyperinsulinism Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Congenital Hyperinsulinism Market Size (2016-2027)
10.2 Middle East & Africa Congenital Hyperinsulinism Market Size by Type
10.2.1 Middle East & Africa Congenital Hyperinsulinism Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Congenital Hyperinsulinism Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Congenital Hyperinsulinism Market Size by Type (2016-2027)
10.3 Middle East & Africa Congenital Hyperinsulinism Market Size by Application
10.3.1 Middle East & Africa Congenital Hyperinsulinism Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Congenital Hyperinsulinism Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Congenital Hyperinsulinism Market Size by Application (2016-2027)
10.4 Middle East & Africa Congenital Hyperinsulinism Market Size by Country
10.4.1 Middle East & Africa Congenital Hyperinsulinism Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Congenital Hyperinsulinism Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 IVAX Pharmaceuticals
11.1.1 IVAX Pharmaceuticals Company Details
11.1.2 IVAX Pharmaceuticals Business Overview
11.1.3 IVAX Pharmaceuticals Congenital Hyperinsulinism Introduction
11.1.4 IVAX Pharmaceuticals Revenue in Congenital Hyperinsulinism Business (2016-2021)
11.1.5 IVAX Pharmaceuticals Recent Development
11.2 Teva Pharmaceuticals
11.2.1 Teva Pharmaceuticals Company Details
11.2.2 Teva Pharmaceuticals Business Overview
11.2.3 Teva Pharmaceuticals Congenital Hyperinsulinism Introduction
11.2.4 Teva Pharmaceuticals Revenue in Congenital Hyperinsulinism Business (2016-2021)
11.2.5 Teva Pharmaceuticals Recent Development
11.3 Zealand Pharma
11.3.1 Zealand Pharma Company Details
11.3.2 Zealand Pharma Business Overview
11.3.3 Zealand Pharma Congenital Hyperinsulinism Introduction
11.3.4 Zealand Pharma Revenue in Congenital Hyperinsulinism Business (2016-2021)
11.3.5 Zealand Pharma Recent Development
11.4 Rezolute
11.4.1 Rezolute Company Details
11.4.2 Rezolute Business Overview
11.4.3 Rezolute Congenital Hyperinsulinism Introduction
11.4.4 Rezolute Revenue in Congenital Hyperinsulinism Business (2016-2021)
11.4.5 Rezolute Recent Development
11.5 Xeris Pharmaceuticals
11.5.1 Xeris Pharmaceuticals Company Details
11.5.2 Xeris Pharmaceuticals Business Overview
11.5.3 Xeris Pharmaceuticals Congenital Hyperinsulinism Introduction
11.5.4 Xeris Pharmaceuticals Revenue in Congenital Hyperinsulinism Business (2016-2021)
11.5.5 Xeris Pharmaceuticals Recent Development
11.6 Eiger BioPharmaceuticals
11.6.1 Eiger BioPharmaceuticals Company Details
11.6.2 Eiger BioPharmaceuticals Business Overview
11.6.3 Eiger BioPharmaceuticals Congenital Hyperinsulinism Introduction
11.6.4 Eiger BioPharmaceuticals Revenue in Congenital Hyperinsulinism Business (2016-2021)
11.6.5 Eiger BioPharmaceuticals Recent Development
11.7 AmideBio
11.7.1 AmideBio Company Details
11.7.2 AmideBio Business Overview
11.7.3 AmideBio Congenital Hyperinsulinism Introduction
11.7.4 AmideBio Revenue in Congenital Hyperinsulinism Business (2016-2021)
11.7.5 AmideBio Recent Development
11.8 Recordati
11.8.1 Recordati Company Details
11.8.2 Recordati Business Overview
11.8.3 Recordati Congenital Hyperinsulinism Introduction
11.8.4 Recordati Revenue in Congenital Hyperinsulinism Business (2016-2021)
11.8.5 Recordati Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Congenital Hyperinsulinism Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Surgery
Table 3. Key Players of Medication
Table 4. Key Players of Others
Table 5. Global Congenital Hyperinsulinism Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Congenital Hyperinsulinism Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Congenital Hyperinsulinism Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Congenital Hyperinsulinism Market Share by Regions (2016-2021)
Table 9. Global Congenital Hyperinsulinism Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Congenital Hyperinsulinism Market Share by Regions (2022-2027)
Table 11. Congenital Hyperinsulinism Market Trends
Table 12. Congenital Hyperinsulinism Market Drivers
Table 13. Congenital Hyperinsulinism Market Challenges
Table 14. Congenital Hyperinsulinism Market Restraints
Table 15. Global Congenital Hyperinsulinism Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Congenital Hyperinsulinism Market Share by Players (2016-2021)
Table 17. Global Top Congenital Hyperinsulinism Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Congenital Hyperinsulinism as of 2020)
Table 18. Ranking of Global Top Congenital Hyperinsulinism Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Congenital Hyperinsulinism Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Congenital Hyperinsulinism Product Solution and Service
Table 22. Date of Enter into Congenital Hyperinsulinism Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Congenital Hyperinsulinism Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Congenital Hyperinsulinism Revenue Market Share by Type (2016-2021)
Table 26. Global Congenital Hyperinsulinism Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Congenital Hyperinsulinism Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Congenital Hyperinsulinism Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global Congenital Hyperinsulinism Revenue Market Share by Application (2016-2021)
Table 30. Global Congenital Hyperinsulinism Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global Congenital Hyperinsulinism Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America Congenital Hyperinsulinism Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Congenital Hyperinsulinism Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Congenital Hyperinsulinism Market Size by Application (2016-2021) (US$ Million)
Table 35. North America Congenital Hyperinsulinism Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America Congenital Hyperinsulinism Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Congenital Hyperinsulinism Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Congenital Hyperinsulinism Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Congenital Hyperinsulinism Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Congenital Hyperinsulinism Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe Congenital Hyperinsulinism Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe Congenital Hyperinsulinism Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Congenital Hyperinsulinism Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Congenital Hyperinsulinism Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Congenital Hyperinsulinism Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Congenital Hyperinsulinism Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific Congenital Hyperinsulinism Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Congenital Hyperinsulinism Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Congenital Hyperinsulinism Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Congenital Hyperinsulinism Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Congenital Hyperinsulinism Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Congenital Hyperinsulinism Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America Congenital Hyperinsulinism Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America Congenital Hyperinsulinism Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Congenital Hyperinsulinism Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Congenital Hyperinsulinism Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Congenital Hyperinsulinism Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Congenital Hyperinsulinism Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa Congenital Hyperinsulinism Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Congenital Hyperinsulinism Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Congenital Hyperinsulinism Market Size by Country (2022-2027) & (US$ Million)
Table 62. IVAX Pharmaceuticals Company Details
Table 63. IVAX Pharmaceuticals Business Overview
Table 64. IVAX Pharmaceuticals Congenital Hyperinsulinism Product
Table 65. IVAX Pharmaceuticals Revenue in Congenital Hyperinsulinism Business (2016-2021) & (US$ Million)
Table 66. IVAX Pharmaceuticals Recent Development
Table 67. Teva Pharmaceuticals Company Details
Table 68. Teva Pharmaceuticals Business Overview
Table 69. Teva Pharmaceuticals Congenital Hyperinsulinism Product
Table 70. Teva Pharmaceuticals Revenue in Congenital Hyperinsulinism Business (2016-2021) & (US$ Million)
Table 71. Teva Pharmaceuticals Recent Development
Table 72. Zealand Pharma Company Details
Table 73. Zealand Pharma Business Overview
Table 74. Zealand Pharma Congenital Hyperinsulinism Product
Table 75. Zealand Pharma Revenue in Congenital Hyperinsulinism Business (2016-2021) & (US$ Million)
Table 76. Zealand Pharma Recent Development
Table 77. Rezolute Company Details
Table 78. Rezolute Business Overview
Table 79. Rezolute Congenital Hyperinsulinism Product
Table 80. Rezolute Revenue in Congenital Hyperinsulinism Business (2016-2021) & (US$ Million)
Table 81. Rezolute Recent Development
Table 82. Xeris Pharmaceuticals Company Details
Table 83. Xeris Pharmaceuticals Business Overview
Table 84. Xeris Pharmaceuticals Congenital Hyperinsulinism Product
Table 85. Xeris Pharmaceuticals Revenue in Congenital Hyperinsulinism Business (2016-2021) & (US$ Million)
Table 86. Xeris Pharmaceuticals Recent Development
Table 87. Eiger BioPharmaceuticals Company Details
Table 88. Eiger BioPharmaceuticals Business Overview
Table 89. Eiger BioPharmaceuticals Congenital Hyperinsulinism Product
Table 90. Eiger BioPharmaceuticals Revenue in Congenital Hyperinsulinism Business (2016-2021) & (US$ Million)
Table 91. Eiger BioPharmaceuticals Recent Development
Table 92. AmideBio Company Details
Table 93. AmideBio Business Overview
Table 94. AmideBio Congenital Hyperinsulinism Product
Table 95. AmideBio Revenue in Congenital Hyperinsulinism Business (2016-2021) & (US$ Million)
Table 96. AmideBio Recent Development
Table 97. Recordati Company Details
Table 98. Recordati Business Overview
Table 99. Recordati Revenue in Congenital Hyperinsulinism Business (2016-2021) & (US$ Million)
Table 100. Recordati Recent Development
Table 101. Research Programs/Design for This Report
Table 102. Key Data Information from Secondary Sources
Table 103. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Congenital Hyperinsulinism Market Share by Type: 2020 VS 2027
Figure 2. Surgery Features
Figure 3. Medication Features
Figure 4. Others Features
Figure 5. Global Congenital Hyperinsulinism Market Share by Application: 2020 VS 2027
Figure 6. Hospital Case Studies
Figure 7. Clinic Case Studies
Figure 8. Others Case Studies
Figure 9. Congenital Hyperinsulinism Report Years Considered
Figure 10. Global Congenital Hyperinsulinism Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 11. Global Congenital Hyperinsulinism Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Congenital Hyperinsulinism Market Share by Regions: 2020 VS 2027
Figure 13. Global Congenital Hyperinsulinism Market Share by Regions (2022-2027)
Figure 14. Global Congenital Hyperinsulinism Market Share by Players in 2020
Figure 15. Global Top Congenital Hyperinsulinism Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Congenital Hyperinsulinism as of 2020
Figure 16. The Top 10 and 5 Players Market Share by Congenital Hyperinsulinism Revenue in 2020
Figure 17. Global Congenital Hyperinsulinism Revenue Market Share by Type (2016-2021)
Figure 18. Global Congenital Hyperinsulinism Revenue Market Share by Type (2022-2027)
Figure 19. North America Congenital Hyperinsulinism Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 20. North America Congenital Hyperinsulinism Market Share by Type (2016-2027)
Figure 21. North America Congenital Hyperinsulinism Market Share by Application (2016-2027)
Figure 22. North America Congenital Hyperinsulinism Market Share by Country (2016-2027)
Figure 23. United States Congenital Hyperinsulinism Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Canada Congenital Hyperinsulinism Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Congenital Hyperinsulinism Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Congenital Hyperinsulinism Market Share by Type (2016-2027)
Figure 27. Europe Congenital Hyperinsulinism Market Share by Application (2016-2027)
Figure 28. Europe Congenital Hyperinsulinism Market Share by Country (2016-2027)
Figure 29. Germany Congenital Hyperinsulinism Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. France Congenital Hyperinsulinism Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. U.K. Congenital Hyperinsulinism Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Italy Congenital Hyperinsulinism Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Russia Congenital Hyperinsulinism Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Nordic Congenital Hyperinsulinism Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Congenital Hyperinsulinism Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Congenital Hyperinsulinism Market Share by Type (2016-2027)
Figure 37. Asia-Pacific Congenital Hyperinsulinism Market Share by Application (2016-2027)
Figure 38. Asia-Pacific Congenital Hyperinsulinism Market Share by Region (2016-2027)
Figure 39. China Congenital Hyperinsulinism Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Japan Congenital Hyperinsulinism Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. South Korea Congenital Hyperinsulinism Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Southeast Asia Congenital Hyperinsulinism Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. India Congenital Hyperinsulinism Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Australia Congenital Hyperinsulinism Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Congenital Hyperinsulinism Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Congenital Hyperinsulinism Market Share by Type (2016-2027)
Figure 47. Latin America Congenital Hyperinsulinism Market Share by Application (2016-2027)
Figure 48. Latin America Congenital Hyperinsulinism Market Share by Country (2016-2027)
Figure 49. Mexico Congenital Hyperinsulinism Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Brazil Congenital Hyperinsulinism Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Congenital Hyperinsulinism Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Congenital Hyperinsulinism Market Share by Type (2016-2027)
Figure 53. Middle East & Africa Congenital Hyperinsulinism Market Share by Application (2016-2027)
Figure 54. Middle East & Africa Congenital Hyperinsulinism Market Share by Country (2016-2027)
Figure 55. Turkey Congenital Hyperinsulinism Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Saudi Arabia Congenital Hyperinsulinism Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. UAE Congenital Hyperinsulinism Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. IVAX Pharmaceuticals Revenue Growth Rate in Congenital Hyperinsulinism Business (2016-2021)
Figure 59. Teva Pharmaceuticals Revenue Growth Rate in Congenital Hyperinsulinism Business (2016-2021)
Figure 60. Zealand Pharma Revenue Growth Rate in Congenital Hyperinsulinism Business (2016-2021)
Figure 61. Rezolute Revenue Growth Rate in Congenital Hyperinsulinism Business (2016-2021)
Figure 62. Xeris Pharmaceuticals Revenue Growth Rate in Congenital Hyperinsulinism Business (2016-2021)
Figure 63. Eiger BioPharmaceuticals Revenue Growth Rate in Congenital Hyperinsulinism Business (2016-2021)
Figure 64. AmideBio Revenue Growth Rate in Congenital Hyperinsulinism Business (2016-2021)
Figure 65. Recordati Revenue Growth Rate in Congenital Hyperinsulinism Business (2016-2021)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed

Global Congenital Hyperinsulinism Treatment Drugs Market Size, Status and Forecast 2021-2027
QFJ1-5672 2021年6月 105Pages
QYResearch社発行の本調査レポートでは、先天性インスリン過剰症治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（ジアゾキシド、オクトレオチド、グルカゴン）、用途別市場規模（病院、診療所、その他）、主要地域別市場規模（北米、アメリカ、欧州...

世界の先天性好中球減少症治療市場規模・現状・予測（2021年-2027年）

Global Congenital Neutropenia Treatment Market Size, Status and Forecast 2021-2027
QFJ1-5131 2021年6月 107Pages
QYResearch社発行の本調査レポートでは、先天性好中球減少症治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（抗生物質、顆粒球コロニー刺激因子（G-CSF）、抗真菌薬）、用途別市場規模（小売薬局、病院薬局、オンライン薬局、その他）、主要地域...

世界のレーバー先天性黒内障（LCA）市場規模・現状・予測（2021年-2027年）

Global Leber Congenital Amaurosis (LCA) Market Size, Status and Forecast 2021-2027
QFJ1-4418 2021年6月 96Pages
QYResearch社発行の本調査レポートでは、レーバー先天性黒内障（LCA）の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（乳幼児タイプ、小児タイプ）、用途別市場規模（病院、眼科クリニック、医療研究所、その他）、主要地域別市場規模（北米、アメリカ...

世界のACTH欠乏症治療市場規模・現状・予測（2021年-2027年）

Global ACTH Deficiency Treatment Market Size, Status and Forecast 2021-2027
QFJ1-3753 2021年6月 99Pages
QYResearch社発行の本調査レポートでは、ACTH欠乏症治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（先天性、後天性）、用途別市場規模（病院、薬局、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東...

世界の時差ボケ治療薬市場規模・現状・予測（2021年-2027年）

Global Jet Lag Therapy Pharmaceuticals Market Size, Status and Forecast 2021-2027
QFJ1-5816 2021年6月 98Pages
QYResearch社発行の本調査レポートでは、時差ボケ治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（Rx、OTC）、用途別市場規模（ビジネス旅行者、キャビンクルー、アスリート、季節旅行者、その他）、主要地域別市場規模（北米、アメリカ、欧州...

世界の海洋由来医薬品市場規模・現状・予測（2021年-2027年）

Global Marine-derived Pharmaceuticals Market Size, Status and Forecast 2021-2027
QFJ1-4462 2021年6月 100Pages
QYResearch社発行の本調査レポートでは、海洋由来医薬品の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（フェノール、ステロイド、エーテル、ペプチド、その他）、用途別市場規模（病院薬局、小売薬局、オンライン薬局）、主要地域別市場規模（北米、アメ...

世界の女性健康用医薬品市場規模・現状・予測（2021年-2027年）

Global Pharmaceuticals for Women's Health Market Size, Status and Forecast 2021-2027
QFJ1-5946 2021年6月 96Pages
QYResearch社発行の本調査レポートでは、女性健康用医薬品の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（顆粒、丸薬、粉末、チンキ剤、錠剤、カプセル、その他）、用途別市場規模（閉経後骨粗鬆症、子宮内膜症、多嚢胞性卵巣症候群、妊娠障害、その他）...

世界のルビプロストン市場規模・現状・予測（2021年-2027年）

Global Lubiprostone Market Size, Status and Forecast 2021-2027
QFJ1-5835 2021年6月 86Pages
QYResearch社発行の本調査レポートでは、ルビプロストンの世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（8mcgカプセル、24mcgカプセル）、用途別市場規模（CIC・OIC、IBS-C）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日...

世界のヒストレリン市場規模・現状・予測（2021年-2027年）

Global Histrelin Market Size, Status and Forecast 2021-2027
QFJ1-5781 2021年6月 85Pages
QYResearch社発行の本調査レポートでは、ヒストレリンの世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（サプレリンLA、ヴァンタス）、用途別市場規模（男の子用、女の子用）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、イン...

世界の製薬における無線周波数認識（RFID）市場規模・現状・予測（2021年-2027年）

Global Radio-Frequency Identification (RFID) in Pharmaceuticals Market Size, Status and Forecast 2021-2027
QFJ1-4790 2021年6月 107Pages
QYResearch社発行の本調査レポートでは、製薬における無線周波数認識（RFID）の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（チップ付きRFID、チップレスRFID）、用途別市場規模（医薬品追跡システム、医薬品品質管理、その他）、主要地域別...

世界の先天性インスリン過剰症治療薬市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Congenital Hyperinsulinism Treatment Drugs Market The global Congenital Hyperinsulinism Treatment Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in an…
世界のレーバー先天性黒内障（LCA）市場規模・現状・予測（2021年-2027年） Leber congenital amaurosis is a kind of autosomal recessive genetic disease, it is the main genetic disease that brings about children blindness, accompany mental nerve symptom, wait like intellectual inferior, hearing obstacle, epilepsy, conus cornea can happen when some age is older or spherical c…
世界の先天性好中球減少症治療市場規模・現状・予測（2021年-2027年） Congenital neutropenia occurs when an individual has low levels of neutrophils, a type of white blood cells. Neutrophils are made in the bone marrow, which is the spongy tissue found in larger bones such as the vertebrae, ribs, and pelvis. The congenital neutropenia treatment include antibiotics, an…
先天性心疾患オクルーダーのグローバル市場調査 2019年 The global Congenital Heart Disease Occluder market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Congenital Heart Disease Occluder volume and value at global level, regional level and company level. Fro…
世界のCOPD用治療薬市場規模・現状・予測（2021年-2027年） Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disease that causes obstructed airflow from the lungs. Symptoms include breathing difficulty, cough, mucus (sputum) production and wheezing. It's typically caused by long-term exposure to irritating gases or particulate matt…